Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 5, 2012, Pages 327-342

  Findling, Robert L ^a   Mckenna, Kathleen ^b   Earley, Willie R ^c   Stankowski, Jill ^d   Pathak, Sanjeev ^e  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d ICON CLINICAL RESEARCH   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BENZATROPINE; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROLACTIN; QUETIAPINE; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL;

ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; AGITATION; AKATHISIA; ANXIETY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DELUSION; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; DYSARTHRIA; DYSKINESIA; DYSPNEA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOKINESIA; INCREASED APPETITE; INSOMNIA; INSULIN BLOOD LEVEL; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY; MUSCLE RIGIDITY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RUBELLA; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT DURATION; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; VISUAL HALLUCINATION; VOMITING; WEIGHT CHANGE; XEROSTOMIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84867811761     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0092     Document Type: Article

References (32)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes.Diabetes Care 27:596-601, 2004.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR).Washington, DC: American Psychiatric Association; 2000.
3. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd ed. Arlington, VA:American Psychiatric Association, 2004.
4. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676, 1989. (Pubitemid 19154942)
5. Brannan AM, Heflinger CA, Bickman L: The caregiver strain questionnaire:Measuring the impact on the family of living with a child with serious emotional disturbance. J Emot Behav Disord 5:212-222, 1997.
6. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
7. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432-1441, 2008.
8. Fleischhaker C, Schulz E, Tepper K, Martin M, Henninghausen K, Remschmidt H: Long-term course of adolescent schizophrenia. Schizophr Bull 31:769-780, 2005. (Pubitemid 41253325)
9. Guy W: Abnormal Involuntary Movement Scale. ECDEU Assessment Manual for Psychopharmacology, revised edition. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
10. Guy W, Bonato RR: CGI Clinical Global Impressions. In: Manual for the ECDEU Assessment Battery. Revised 2nd ed. Chevy Chase, MD: US Department of Health, Education and Welfare; 1970; pp. 12-1-12-6.
11. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF: A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 19:611-621, 2009.
12. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for affective disorders and schizophrenia for school-age children - present and lifetime version (K SADSPL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997. (Pubitemid 27272932)
13. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS). Schizophr Bull 13:261-276, 1987. (Pubitemid 18039085)
14. Krausz M, Müller-Thomsen T: Schizophrenia with onset in adolescence: An 11-year followup. Schizophr Bull 19:831-841, 1993. (Pubitemid 23339439)
15. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M: Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:60-70, 2009.
16. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Charles Schulz S: Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34:60-71, 2008. (Pubitemid 350262286)
17. Lay B, Blanz B, Hartmann M, Schmidt M: The psychosocial outcome of adolescent schizophrenia: A 12-year followup. Schizophr Bull 26:801-816, 2000.
18. McConville BJ, Arvanitis LA, Thyrun PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000. (Pubitemid 30305366)
19. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812, 1962
20. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043, 2007. (Pubitemid 47121392)
21. Reichert A, Kreiker S, Mehler-Wex C, Warnke A: The psychopathological and psychosocial outcome of early-onset schizophrenia: Preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health 2:6, 2008.
22. Riedel M, Muller N, Strassnig M, Spellman I, Severus E, Moller H-J: Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatr Dis Treat 3:219-235, 2007. (Pubitemid 46864061)
23. Schimmelmann BG, Mehler-Wex C, Lambert M, Schulze-zur-Wiesch C, Koch E, Flechtner HH, Gierow B, Maier J, Meyer E, Schulte-Markwort M: A prospective 12 week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 17:768-778, 2007. (Pubitemid 351158602)
24. Seroquel- (Quetiapine Fumarate) Prescribing Information; 2011. Available at: Http://www1.astrazeneca-us.com/pi/Seroquel.pdf. Last accessed September 20, 2012.
25. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983. (Pubitemid 13015019)
26. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415-424, 2001. (Pubitemid 34117291)
27. Shaw P, Rapaport J: Decision making about children with psychotic symptoms: Using the best evidence in choosing a treatment. J Am Acad Child Adolesc Psychiatry 45:1381-1386, 2006. (Pubitemid 44665456)
28. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL: Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.Arch Gen Psychiatry 63:721-730, 2006.
29. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA: Doubleblind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder:findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420-1431, 2008.
30. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 Suppl 44:11-19, 1970.
31. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 54:549-557, 1997. (Pubitemid 27258553)
32. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA: Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 67:1093-1103, 2006. (Pubitemid 44230881)